Skip to main content
SpringerLink
Log in

Neurodegenerative disease

A neural stem-cell treatment for progressive multiple sclerosis

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A phase 1 trial using an allogeneic stem-cell-based therapy in people with progressive multiple sclerosis (MS) shows the feasibility and tolerability of the approach; rigorous evaluation of this and other regenerative strategies for MS is now urgently needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Schematics of the phase 1 STEMS clinical trial in people with progressive multiple sclerosis.

References

  1. Pluchino, S., Smith, J. A. & Peruzzotti-Jametti, L. Trends Mol. Med. 26, 898–912 (2020).

    Article  CAS  Google Scholar 

  2. Genchi, E., Brambilla, E., Sangalli, F. & Martino, G. Nat. Med. https://doi.org/10.1038/s41591-022-02097-3 (2023).

  3. Lindvall, O. et al. Lancet 332, 1483–1484 (1988).

    Article  Google Scholar 

  4. Mazzini, L. et al. Stem Cells Transl. Med. 8, 887–897 (2019).

    Article  Google Scholar 

  5. Baloh, R. H. et al. Nat. Med. 28, 1813–1822 (2022).

    Article  CAS  Google Scholar 

  6. Leone, M. et al. Preprint at http://medrxiv.org/lookup/doi/10.1101/2022.11.14.22282124 (2022).

  7. Harris, V. K. et al. Neurol. Neuroimmunol. Neuroinflamm. 8, e928 (2021).

    Article  Google Scholar 

  8. Petrou, P. et al. Brain 143, 3574–3588 (2020).

    Article  Google Scholar 

  9. Uccelli, A. et al. Lancet Neurol. 20, 917–929 (2021).

    Article  CAS  Google Scholar 

  10. Yamanaka, S. Cell Stem Cell 27, 523–531 (2020).

    Article  CAS  Google Scholar 

  11. Deinsberger, J., Reisinger, D. & Weber, B. NPJ Regen. Med. 5, 15 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The New York Stem Cell Foundation Research Institute, New York, NY, USA

    Valentina Fossati

  2. Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, UK

    Luca Peruzzotti-Jametti & Stefano Pluchino

Authors
  1. Valentina Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Peruzzotti-Jametti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefano Pluchino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentina Fossati.

Ethics declarations

Competing interests

S.P. is founder, chief scientific officer and shareholder (>5%) of CITC Ltd and chair of the scientific advisory board at ReNeuron plc. The other authors have no conflicts to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fossati, V., Peruzzotti-Jametti, L. & Pluchino, S. A neural stem-cell treatment for progressive multiple sclerosis. Nat Med 29, 27–28 (2023). https://doi.org/10.1038/s41591-022-02164-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02164-9

  • Springer Nature America, Inc.

Search

Navigation